Sarcopenia is a condition, which is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging.
This disease's physical consequences put a person at risk for falls, fractures, and hospitalization, hence affecting the quality of life and death in extreme cases.
Sarcopenia's etiology constellates factors consisting of the aging neuromuscular machinery, decreased anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic, and behavioral factors.
Sarcopenia Treatments have aimed mostly on extrinsic approaches such as exercise and diet, but the latest scientific advances have brought greater attention to more treatment options. Trials with several agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options.
To date, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. To achieve that, increased awareness of Sarcopenia is of great importance to begin reaching consensus on diagnosis and finding a cure for this condition.
Sarcopenia Epidemiological Segmentation
The Epidemiological Segmentation of Sarcopenia in 7MM from 2017 to 2030 is segmented as:-
- Prevalent Cases of Sarcopenia
- Prevalence of Sarcopenia by Gender
- The total prevalent population of Sarcopenia in 7MM in 2017 was 33,321,576
- The total prevalent cases of Sarcopenia in the United States in 2017 were 17,800,538
The therapeutic market of Sarcopenia in 7MM in 2017 was USD 1166.26 Million
Sarcopenia Market Drivers
- Better insights into disease intervention
- Increase in research initiatives
- Need for a cost-effective therapy
Sarcopenia Market Barriers
- Need for screening tools
- Implementation of interventions
- Diagnosis associated shortcomings
Sarcopenia Emerging Drugs
The emerging drugs of the Sarcopenia market are
And many others.
Sarcopenia Key Players
The key players in the Sarcopenia market are
And many others.